A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2011
12/08/2011	WO2011152516A1 Anti-tumor agent combined with kinase inhibitor
12/08/2011	WO2011152515A1 Antitumor agent containing indole compound
12/08/2011	WO2011152508A1 Optically active dibenzylamine derivative, and manufacturing method for same
12/08/2011	WO2011152485A1 Novel 4,5-fused pyrimidine derivative
12/08/2011	WO2011152351A1 Purinone derivative
12/08/2011	WO2011152330A1 Soybean protein hydrolysate-containing antioxidant and use thereof
12/08/2011	WO2011152100A1 Mesenchymal stem cell inducer, and method for induction of mesenchymal stem cell
12/08/2011	WO2011152071A1 Novel hyaluronic acid decomposition-promoting factor and inhibitor thereof
12/08/2011	WO2011151941A1 Composition having activity of inducing proliferation or accumulation of regulatory t cell
12/08/2011	US20110301525 Biomaterials for tissue replacement
12/08/2011	US20110301231 Lipase inhibiting composition
12/08/2011	US20110301217 Selective Glycosidase Inhibitors and Uses Thereof
12/08/2011	US20110301213 Use of pilocarpine for hypoptyalism treatment
12/08/2011	US20110301203 Chemical compounds
12/08/2011	US20110301191 Methods of treatment using selective 5-ht2a inverse agonists
12/08/2011	US20110301181 halogen-substituted compounds
12/08/2011	US20110301168 Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors
12/08/2011	US20110301158 Aryl carbonyl derivatives as therapeutic agents
12/08/2011	US20110301134 Alkyne antagonists of lysophosphatidic acid receptors
12/08/2011	US20110301127 Methods of reducing microbial resistance to drugs
12/08/2011	US20110301102 Compositions and methods for treating myelodysplastic syndrome
12/08/2011	US20110301097 Oral Administration Of Therapeutic Agent Coupled To Transporting Agent
12/08/2011	US20110301096 Prodrug of an ice inhibitor
12/08/2011	US20110300241 Oral care compositions for treating xerostomia
12/08/2011	US20110300237 Protective solutions for organs
12/08/2011	US20110300224 Taste masked dosage form of pharmaceutically acceptable salt of escitalopram
12/08/2011	US20110300212 Pharmaceutical Formulation
12/08/2011	US20110300211 Soft-gelatin capsule formulation
12/08/2011	US20110300160 Sulfation of wnt pathway proteins
12/08/2011	US20110300142 Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
12/08/2011	US20110300139 Generation, expression and characterization of the humanized k33n monoclonal antibody
12/08/2011	US20110300136 Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
12/08/2011	US20110300130 Impaired wound healing compositions and treatments
12/08/2011	US20110300124 Soaking agent for the treatment of hemorrhoids and method of use
12/08/2011	US20110300116 Method for Generating a Recombinant Clonal Cell Line and Novel Reagents for Use in the Method
12/08/2011	US20110300115 Use of inductor agents gse24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence
12/08/2011	US20110300096 Polymers With Structure-Defined Functions
12/08/2011	CA2801417A1 Optically active dibenzylamine derivative, and method for preparing thereof
12/08/2011	CA2800523A1 Purinone derivative
12/07/2011	EP2392573A1 Quinoline derivative
12/07/2011	EP2392561A1 Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
12/07/2011	EP2392323A1 Prostate cancer progression inhibitor and progression inhibition method
12/07/2011	EP2391386A1 Oligomer-phenothiazine conjugates
12/07/2011	EP1802291B1 Calixarene-based peptide conformation mimetics, methods of use, and methods of making
12/07/2011	EP1294770B1 Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
12/07/2011	CN1494425B 用作治疗剂的羧酰胺衍生物 As therapeutic agents carboxamide derivatives
12/07/2011	CN102272302A 增强重组蛋白表达的方法 Method for enhancing the expression of the recombinant protein
12/07/2011	CN102271685A 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物 Identification develop into an increased risk of organ failure in critically ill patients for their treatment methods and compounds
12/07/2011	CN102271667A 用于治疗椎管狭窄的5-ht2a和5-ht2b受体拮抗剂 For the treatment of spinal stenosis 5-ht2a receptor antagonist and 5-ht2b
12/07/2011	CN102269766A 人类基因fam96a及其蛋白质的应用 Human genes and proteins applications fam96a
12/07/2011	CN102267981A 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的盐 4-Methyl -n- [3- (4- methyl - imidazol-1-yl) -5-trifluoromethyl - phenyl] -3- (4-pyridin-3-yl - pyrimidin-2-yl amino) - benzamide salt
12/07/2011	CN102266571A microRNA 302在早期胚胎发育中的应用 microRNA 302 used in the early embryonic development
12/07/2011	CN102266548A 一种治疗母猪低温症的中药组合物 A treatment for hypothermia sow Chinese medicinal composition
12/07/2011	CN102078497B 中药组方复方防啄散及其施用方法 Chinese Traditional Medicine Compound scattered anti-peck method and its application
12/07/2011	CN101961437B 一种抗应激复方制剂及其制备工艺 An anti-stress compound preparation and preparation process
12/07/2011	CN101574552B 含有噻托铵吸入用粉末的吸入用套盒 Tiotropium containing inhalation powder inhalation kit
12/07/2011	CN101357893B 乙二胺类金属蛋白酶抑制剂及其应用 Ethylenediamines metalloproteinase inhibitor and its application
12/07/2011	CN101301102B 一种防暑功能性饮料 One kind of functional beverages heatstroke
12/07/2011	CN101121021B 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 Humanized anti-ErbB2 antibody treatment with anti-ErbB2 antibody and carried out
12/07/2011	CN101102795B 用于抑制纤维化的药物载体和药物载体试剂盒 Drug carrier for inhibiting fibrosis and drug carrier kit
12/06/2011	USRE43003 Epothilone derivatives
12/06/2011	US8071729 Anti-integrin antibodies, compositions, methods and uses
12/06/2011	US8071604 Thio-substituted arylmethanesulfinyl derivatives
12/06/2011	US8071564 Regulation of angiogenesis with zinc finger proteins
12/06/2011	US8071333 Anti-integrin antibodies, compositions, methods and uses
12/06/2011	US8071120 biodegradable drug delivery system containing an immunosuppressive agent and a bioerodible polymer comprising hydroxyaliphatic carboxylic acids, and polysaccharides
12/06/2011	US8071096 Anti-C5aR antibodies and uses thereof
12/06/2011	US8071074 e.g. (6,7-(dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine; epidermal growth factor receptor (EGF-R) antagonist, tyrosine kinase inhibitor; hypersecretion of mucus in lungs: chronic bronchitis, acute asthma, cystic fibrosis, bronchiectasis, chronic obstructive lung disease
12/06/2011	CA2491243C Viral inhibitors
12/06/2011	CA2485430C Process for the preparation of a hydrate of an anthranilic acid derivative
12/06/2011	CA2470837C Matrix-forming composition containing pectin
12/06/2011	CA2470791C Soft drink replacer
12/06/2011	CA2455620C Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
12/06/2011	CA2387922C Inhibition of cell motility and angiogenesis
12/06/2011	CA2383522C Neurotherapeutic composition and method
12/06/2011	CA2380858C Inhibitors of aspartyl protease
12/06/2011	CA2364386C Method for producing interleukin-1 receptor antagonists, a therapeutic activity protein, from body fluids
12/06/2011	CA2361766C Gcsf conjugates
12/06/2011	CA2345287C Tgf-beta superfamily mutant members, including morphogenic proteins
12/06/2011	CA2309954C Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
12/06/2011	CA2301333C Prb2/p130 peptide inhibitors of cdk2 kinase activity
12/01/2011	WO2011149051A1 Antitumor t cell response enhancer
12/01/2011	WO2011149046A1 Therapeutic agent for pancreatic cancer
12/01/2011	WO2011149036A1 Anti-inflammatory drug
12/01/2011	WO2011149025A1 Body temperature rising agent for oral administration
12/01/2011	WO2011148922A1 Novel quinazoline compound
12/01/2011	WO2011148888A1 Heterocyclic ring compound and h1 receptor antagonist
12/01/2011	WO2011148657A1 Composition for prevention, amelioration or treatment of metabolic syndrome
12/01/2011	WO2011147926A2 Magnetically responsive membrane structures
12/01/2011	WO2011147588A1 Compositions for use in genetic disorders comprising 4-phenyl- butyric acid and its salts
12/01/2011	WO2011147587A1 Compositions for use in cardiovascular diseases comprising 4 - phenyl - butyric acid and its salts
12/01/2011	WO2011147586A1 Compositions for use in neurological or neurodegenerative diseases with a genetic disorder background comprising 4-phenyl-butyric acid and its salts
12/01/2011	WO2011147585A1 Compositions for use in the treatment of immune diseases, comprising 4 - phenyl -butyric acid and its salts
12/01/2011	WO2011147584A1 Compositions for use in genetic disorders causative for cystic fibrosis comprising 4-phenyl-butyric acid and its salts
12/01/2011	WO2011079213A9 Treating critically ill patients with intravenous ibuprofen
12/01/2011	US20110296542 Exogenous matrix-supported topical application of stem cells to organ surface
12/01/2011	US20110294882 Novel derivatives of 3,3-diphenylpropylamines
12/01/2011	US20110294870 Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
12/01/2011	US20110294857 Inhibitor of casein kinase 1delta and casein kinase 1epsilon
12/01/2011	US20110294820 N-Oxides of n-Phenyl-2-pyrimidine-amine Derivatives

1 ... 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 ... 1564